Alcohol-use disorders (AUD) pose a significant challenge for the United States (US) military. The US Department of Defense has strongly recommended several medications for use in the treatment of patients with diagnosed AUD. This study assessed the prescription of medications for active duty service members (ADSMs) diagnosed with AUD in the US Military Health System (MHS).
Methods
Rates of prescription orders were retrospectively examined from 2010 to 2017 among ADSMs with an incident diagnosis of moderate-to-severe AUD. The rate of prescription orders was defined as the proportion of ADSMs with an ICD-9 or ICD-10 diagnosis code of alcohol dependence who received an order for acamprosate, disulfiram, naltrexone, and/or topiramate at a military treatment facility in the year following their incident diagnosis.
Results
ADSMs receiving an order for at least one medication in the year following their incident AUD diagnosis increased from 8.8% in 2010 to 16.2% in 2017 (RR = 1.84, 95% CI, 1.76, 1.93). Oral naltrexone was ordered most frequently among this patient population, while injectable naltrexone, a medication option meant to ease and improve adherence, was ordered for a smaller proportion of patients.
Conclusions
Most ADSMs who might benefit from prescriptions for AUD are not receiving them as part of their treatment despite strong clinical evidence and Department of Defense policy support for their use among this cohort.
SacksJJ, GonzalesKR, BoucheryEE, . 2010 national and state costs of excessive alcohol consumption. Am J Prev Med. 2015;49(5):73–79.
3.
SaitzR.Clinical practice. Unhealthy alcohol use. N Engl J Med. 2005;352(6):596–607.
4.
StahreM, RoeberJ, KannyD, . Contribution of excessive alcohol consumption to deaths and years of potential life lost in the United States. Prev Chronic Dis. 2014;11:130293. http://doi.org/10.5888/pcd11.130293
BrayRM, PembertonMR, HouraniLL, . 2008 Department of Defense Survey of Health Related Behaviors among Active Duty Military Personnel. Research Triangle Park, NC: Research Triangle Institute; 2009.
7.
BrayRM, PembertonMR, LaneME, . Substance use and mental health trends among U.S. military active duty personnel: key findings from the 2008 DoD Health Behavior Survey. Mil Med. 2010;175(6):390–399.
8.
BrayRM, HouraniLL.Substance use trends among active duty military personnel: findings from the United States Department of Defense Health Related Behavior Surveys, 1980–2005. Addiction. 2007;102(7):1092–1101.
HarwoodHJ, ZhangY, DallTM, . Economic implications of reduced binge drinking among the Military Health System's TRICARE prime plan beneficiaries. Mil Med. 2009;174(7):728–736.
11.
Armed Forces Health Surveillance Branch. Alcohol-related diagnoses, active component, U.S. Armed Forces, 2001–2010. MSMR. 2011;18(10):9–13.
12.
BenjaminKL, BellNS, HollanderIE.A historical look at alcohol abuse trends in Army and civilian populations. Mil Med. 2007;172(9):950–955.
Institute of Medicine. Substance Use Disorders in the U.S. Armed Forces. Washington, DC: The National Academies Press. 2013.
15.
United States Department of Veterans Affairs & Department of Defense. VA/DoD clinical practice guideline for the management of substance use disorders (Version 3.0). Washington, D.C.: VA/DOD Evidence Based Practice Guideline Work Group; 2015. https://www.healthquality.va.gov/guidelines/mh/sud/.
JonasDE, AmickHR, FeltnerC, . Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA. 2014;311(18):1889–1900.
19.
RösnerS, Hackl-HerrwerthA, LeuchtS, . Opioid antagonists for alcohol dependence. Cochrane Database Syst Rev. 2010;(12):CD001867. Published 2010 Dec 8. http://doi.org/10.1002/14651858.CD001867.pub2.
20.
GarbuttJC, KranzlerHR, O'MalleySS, Vivitrex Study Group, . Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: A randomized controlled trial. JAMA. 2005;293(13):1617–1625.
21.
HarrisAHS, BoweT, Del ReAC, . Extended release naltrexone for alcohol use disorders: Quasi-experimental effects on mortality and subsequent detoxification episodes. Alcohol Clin Exp Res. 2015;39(1):79–83.
22.
AbrahamAJ.Improving medication use in addictions treatment. Vol. 3. In: MillerPM, ed. Comprehensive Addictive Behaviors and Disorders. New York: Elsevier; 2013: 675–685
23.
JohnsonBA, Ait-DaoudN, BowdenCL, . Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet. 2003;361(9370):1677–1685.
24.
JohnsonBA, RosenthalN, CapeceJA, . Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA. 2007;298(14):1641–1651.
25.
RieckmannT, MuenchJ, McBurnieMA, . Medication-assisted treatment for substance use disorders within a national community health center research network. Subst Abus. 2016;37(4):625–634.
26.
KnudsenHK, RomanPM.Service delivery and pharmacotherapy for alcohol use disorder in the era of health reform: data from a national sample of treatment organizations. Subst Abus. 2016;37(1):230–237.
27.
KnudsenHK, RomanPM.Dissemination, adoption, and implementation of acamprosate for treating alcohol use disorders. J Stud Alcohol Drugs. 2014;75(3):467–475.
28.
KnudsenHK, AbrahamAJ, RomanPM.Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21–27.
29.
United States Department of Veterans Affairs & Department of Defense.VA/DoD Clinical Practice Guideline for the Management of Substance Use Disorders (Version 2.0). Washington, D.C.: VA/DOD Evidence Based Practice Guideline Work Group; 2009. https://www.healthquality.va.gov/guidelines/MH/sud/sud_full_601f.pdf.
30.
Del ReAC, GordonAJ, LembkeA, . Prescription of topiramate to treat alcohol use disorders in the Veterans Health Administration. Addict Sci Clin Pract. 2013;8(1):12.
31.
HarrisAH, KivlahanDR, BoweT, . Pharmacotherapy of alcohol use disorders in the Veterans Health Administration. Psychiatr Serv. 2010;61(4):392–398.
WitkiewitzK, RoosCR, MannK, . Advancing precision medicine for alcohol use disorder: replication and extension of reward drinking as a predictor of naltrexone response. Alcohol Clin Exp Res. 2019;43(11):2395–2405.
36.
AntonRF, LathamPK, VoroninKE, . Nicotine-use/smoking is associated with the efficacy of naltrexone in the treatment of alcohol dependence. Alcohol Clin Exp Res. 2018;42(4):751–760.
37.
FucitoLM, ParkA, GulliverSB, . Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence. Biol Psychiatry. 2012;72(10):832–838.
38.
WitkiewitzK, VotawVR, VowlesKE, . Opioid misuse as a predictor of alcohol treatment outcomes in the COMBINE study: mediation by medication adherence. Alcohol Clin Exp Res. 2018;42(7):1249–1259.
39.
KranzlerHR.Pharmacotherapy of alcoholism: gaps in knowledge and opportunities for research. Alcohol. 2000;35(6):537–547.
40.
AbrahamAJ, RomanPM.Early adoption of injectable naltrexone for alcohol-use disorders: findings in the private-treatment sector. J Stud Alcohol Drugs. 2010;71(3):460–466.
41.
AdamsRS, DietrichEJ, GrayJC, . Post-deployment screening in the Military Health System: an opportunity to intervene for possible alcohol use disorder. Health Aff. 2019;38(8):1298–1306.
42.
AllenB, NolanML, PaoneD.Underutilization of medications to treat opioid use disorder: what role does stigma play?Subst Abus. 2019;40(4):459–465.
43.
RobinsonSM, AdinoffB.The mixed message behind “medication-assisted treatment” for substance use disorder. Am J Drug Alcohol Abuse. 2018;44(2):147–150.
44.
GuglielmoR, MartinottiG, QuatraleM, . Topiramate in alcohol use disorders: review and update. CNS Drugs. 2015;29(5):383–395.
45.
AletrarisL, Bond EdmondM, RomanPM.Adoption of injectable naltrexone in U.S. substance use disorder treatment programs. J Stud Alcohol Drugs. 2015;76(1):143–151.
46.
HarrisAHS, EllerbeL, ReederRN, . Pharmacotherapy for alcohol dependence: Perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013;10(4):410–419.
47.
HarrisAHS, BoweT, HagedornH, . Multifaceted academic detailing program to increase pharmacotherapy for alcohol use disorder: interrupted time series evaluation of effectiveness. Addict Sci Clin Pract. 2016;11(1):15.
48.
HouraniL, BenderR, WeimerB, . Comparative analysis of mandated versus voluntary administrations of post-deployment health assessments among marines. Mil Med. 2012;177(6):643–648.
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
